NOACs in Oral and Maxillofacial Surgery: Impact on Post-operative Complications

Sponsor
Malmö University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04662515
Collaborator
Odontologisk Forskning i Region Skåne (OFRS) (Other)
300
2
127
150
1.2

Study Details

Study Description

Brief Summary

Aims: To investigate the incidence of bleeding complications during oral surgical procedures in patients medicated with DOACs.

To investigate the perioperative and postoperative bleeding volume during oral surgical procedures in patients medicated with DOACs.

To examine whether increased perioperative bleeding volume complicates the planned intervention, thereby prolonging the operation time.

Previous studies have shown that the incidence of healthcare-consuming bleeding complications following oral surgical procedures in patients who are prescribed warfarin is approximately 4% (9). To investigate whether the incidence is higher or lower by the intake of DOAC it is considered to be sufficient with 100 patients in each group. The groups consist of patients who are prescribed warfarin, DOACs, as well as a control group.

Hypothetical outcomes: The incidence of bleeding complications and the perioperative and postoperative bleeding volume during oral surgical procedures in patients medicated with DOACs are higher compared to patients medicated with warfarin and patients taking no anticoagulants. Increased perioperative bleeding volume complicates the planned intervention, thereby prolonging the operation time.

Clinical relevance: The study will serve as a basis for the development of treatment guidelines for patients who medicate with DOACs. If it turns out that the oral surgery procedure presents no increased risk of complications and that the bleeding volume does not complicate the surgery significantly, it may be recommended that patients who medicate with DOACs whom are in need of oral surgical procedures seek ordinary dental care.

Detailed Description

The continuous variables (amount of bleeding during surgery) will be analyzed with linear regression if they show normal distribution patterns.

The ordinal variables (postoperative bleeding complications) will be analyzed with ordinal logistic regression.

Dichotomous variables (presence of other postoperative complications) will be analyzed with logistic regression.

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Novel Oral Anticoagulants in Oral and Maxillofacial Surgery: Impact on Bleeding Tendency, Surgical Difficulty and Post-operative Complications
Actual Study Start Date :
Jun 1, 2016
Anticipated Primary Completion Date :
Dec 31, 2026
Anticipated Study Completion Date :
Dec 31, 2026

Arms and Interventions

Arm Intervention/Treatment
DOAC

Information about which type of DOAC and the dose that is prescribed to the patient will be collected.

Procedure: Type of surgery
surgical or non-surgical extraction one or more teeth

Drug: Dabigatran

Drug: Rivaroxaban

Drug: Apixaban

Drug: Edoxaban

Warfarin

A PK-INR ≤3.0 retained whitin the last 24 hours have to be present for inclusion.

Procedure: Type of surgery
surgical or non-surgical extraction one or more teeth

Drug: Warfarin

No blood thinners

Procedure: Type of surgery
surgical or non-surgical extraction one or more teeth

Outcome Measures

Primary Outcome Measures

  1. bleeding complication [4 weeks postoperatively]

    proportion of patients who are in need of non planned/emergency medical or dental care after tooth extraction / oral surgery because of bleeding

Secondary Outcome Measures

  1. bleeding volume [the actual time of surgery]

    the amount of blood that the patient is bleeding during tooth extraction / oral surgery

  2. surgical difficulty [the actual time of surgery]

    estimation on a scale of 1-10 by the surgeon

  3. surgery time in minutes [the actual time of surgery]

  4. proportion of other postoperative complications [4 weeks postoperatively]

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
Need of dental extraction / oral surgery, and medication with:
  1. warfarin or

  2. DOACs or

  3. no treatment or AK-platelet therapy and age-matched to group a) and b).

Exclusion Criteria:

Medication with the combination of anticoagulants and antiplatelet Ongoing drug abuse

Contacts and Locations

Locations

Site City State Country Postal Code
1 Skåne University Hospital Helsingborg Sweden SE - 251 87
2 Department of Oral and Maxillofacial Surgery and Oral Medicine, Faculty of Odontology, Malmö University Malmö Sweden S-20506

Sponsors and Collaborators

  • Malmö University
  • Odontologisk Forskning i Region Skåne (OFRS)

Investigators

  • Study Director: Jonas P becktor, DDS, PhD, Faculty of Odontology, Malmö University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Krister Johansson, Dr Krister Johansson. Department of Oral and Maxillofacial Surgery and Oral Medicine, Faculty of Odontology, Malmö University, Malmö University
ClinicalTrials.gov Identifier:
NCT04662515
Other Study ID Numbers:
  • AK-BLD
First Posted:
Dec 10, 2020
Last Update Posted:
Apr 12, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 12, 2022